Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deupirfenidone (LYT-100) and Nintedanib DDI Study in Healthy Volunteers
NCT06717100Phase 1Completed
- Sponsor
- PureTech Health
- Start
- Dec 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of deupirfenidone in idiopathic pulmonary fibrosis (IPF), sponsored by PureTech Health. Primary endpoints: Area Under the Curve at Day 30, Time to Maximum Plasma Concentration at Day 30 and 1 more. Started Dec 2024; status: completed.
02
Drugs
deupirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06717100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06717100.